Psilocybin for End-of-Life Anxiety: What the Research Shows
Research into psilocybin for end-of-life anxiety has produced some of the most compelling clinical data in psychedelic science. Landmark trials at Johns Hopkins and NYU found...
Psychedelic Therapy in Arizona: Ketamine, Laws, and Support
Last Updated: May 2026 Psychedelic therapy in Arizona currently means ketamine, which is legal, widely available in Scottsdale and Phoenix, and supported by a growing number...
Ibogaine Opioid Treatment Research: What 2025-2026 Studies Found
Ibogaine opioid treatment research has moved significantly forward in 2025 and 2026, with new clinical data, a landmark $50 million Texas state investment, and a federal...
Psychedelic Therapy Washington DC, Maryland & Virginia: 2026 Guide
Last Updated: May 2026 If you’re looking for psychedelic therapy in Washington DC, Maryland, or Virginia (DMV), your clearest option right now is ketamine, which is...
Executive Burnout Psychedelic Therapy: What the Research Shows
Executive burnout psychedelic therapy is moving from the research margins into serious clinical conversation. A growing body of peer-reviewed evidence suggests that psilocybin-assisted therapy can reduce...
Psychedelic Therapy in New York City: Ketamine, Legal Options, and What’s Next
Last Updated: May 2026 Psychedelic therapy in New York City is a real and growing option, but the legal landscape is still uneven. Ketamine therapy is...
Psilocybin Alcohol Use Disorder: What Hopkins and NYU Research Found
Research on psilocybin alcohol use disorder treatment, including a landmark 2022 randomized controlled trial published in JAMA Psychiatry, has shown meaningful reductions in heavy drinking days...
Psilocybin PTSD Therapy: What the 2026 Clinical Evidence Shows
Psilocybin PTSD therapy is no longer a fringe concept. A growing body of clinical research, including Phase 2 trials published in 2025, shows that a single...
Set and Setting in 2026: A Psychedelic Preparation Guide for High-Performers
Set and setting psychedelics research refers to the two core non-pharmacological factors that shape a psilocybin experience: your internal state (set) and the physical and relational...
Psychedelics for Depression: What the 2026 Research Actually Shows
Quick Answer Psilocybin and other psychedelics show real, measurable promise for depression, particularly treatment-resistant cases. But the evidence in 2026 is more complicated, more honest, and...
Ready to take the next step?
Start with a complimentary conversation, or take the two-minute self-evaluation to see if this is your moment.